One-year cumulative incidence of respiratory infections after BCMA–directed CAR T-cell therapy. The 1-year cumulative incidence of respiratory infections accounting for competing risks of infection-free death and disease relapse requiring antineoplastic treatment was 22% (95% CI, 15-32).